Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category

被引:39
作者
Bacher, Ulrike [1 ]
Schnittger, Susanne [2 ]
Kern, Wolfgang [2 ]
Weiss, Tamara [2 ]
Haferlach, Torsten [2 ]
Haferlach, Claudia [2 ]
机构
[1] Univ Med Ctr Hamburg UCCH, Clin Stem Cell Transplantat, D-20246 Hamburg, Germany
[2] MLL Munich Leukemia Lab, Munich, Germany
关键词
Myelodysplastic syndromes (MDS); Myeloproliferative neoplasms (MPN); Myelodysplastic/myeloproliferative neoplasms (MDS/MPN); Cytogenetics; Molecular mutations; ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; JAK2 V617F MUTATION; N-RAS MUTATIONS; FAB SUBTYPES; CHROMOSOME; FLT3; PROGNOSIS; DISORDERS; DISEASES;
D O I
10.1007/s00277-009-0745-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
According to the new World Health Organization (WHO) classification (2008), chronic myeloid malignancies are divided in myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), and overlap MDS/MPN cases. From morphological aspects, these categories show overlaps. To evaluate whether these morphological similarities have genetic parallels, we investigated 1,851 cases with suspected/confirmed myelodysplastic or myeloproliferative diseases by chromosome banding and molecular analyses. Cytogenetics revealed aberrant karyotypes in 354 patients (19.1% of the original cohort) who were the basis of further analysis. The distribution of chromosomal aberrations differed significantly between categories. Isolated +9 and gain of 9p were exclusively observed in MPN (+9: 10/93; 11%; p < 0.001; +9p: 6/93; 7% of all aberrant MPN cases) but were not detected in MDS or MDS/MPN (p = 0.001). Isolated del(5q) (p = 0.002), -7 in combination with other aberrations (p = 0.016), and complex aberrations (p = 0.003) were 2.9- to 7.5-fold more frequent in MDS than in MPN. Trisomies 8 and 21 and del(20q) were comparably frequent in both subgroups. Interestingly, the MDS/MPN overlap cohort showed a higher frequency of -7 accompanied by other aberrations (3/17; 18% of all aberrant cases; p = 0.001), i(17)(q10) (2/17; 12%; p = 0.013), and +21 (2/17; 12%; p = 0.013) when compared to MPN or MDS only. These differences support the category for MDS/MPN within the new WHO classification. Overlaps between the diverse disorders were seen also for the JAK2V617F (MPN 66/89; 74%; MDS/MPN 4/14; 29%; MDS 2/63; 3%) and NRAS mutations (MDS 2/67; 3%; MPN 2/4; MDS/MPN 1/1). In conclusion, cytogenetics and molecular genetics show overlaps in varying proportions of MDS and MPN cases which might indicate common pathways in their etiology. Some markers are strongly associated with one of these disorders and can be helpful for differential diagnosis especially in difficult cases.
引用
收藏
页码:1207 / 1213
页数:7
相关论文
共 41 条
[1]  
Asimakopoulos FA, 1996, BRIT J HAEMATOL, V95, P219
[2]   Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information [J].
Bacher, U ;
Haferlach, T ;
Kern, W ;
Hiddemann, W ;
Schnittger, S ;
Schoch, C .
ANNALS OF HEMATOLOGY, 2005, 84 (04) :250-257
[3]   A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia [J].
Bacher, Ulrike ;
Haferlach, Torsten ;
Kern, Wolfgang ;
Haferlach, Claudia ;
Schnittger, Susanne .
HAEMATOLOGICA, 2007, 92 (06) :744-752
[4]   Implications of NRAS mutations in AML:: a study of 2502 patients [J].
Bacher, Ulrike ;
Haferlach, Torsten ;
Schoch, Claudia ;
Kern, Wolfgang ;
Schnittger, Susanne .
BLOOD, 2006, 107 (10) :3847-3853
[5]   The relationship between the myelodysplastic syndromes and the myeloproliferative disorders [J].
Bain, BJ .
LEUKEMIA & LYMPHOMA, 1999, 34 (5-6) :443-+
[6]   Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].
Baxter, EJ ;
Scott, LM ;
Campbell, PJ ;
East, C ;
Fourouclas, N ;
Swanton, S ;
Vassiliou, GS ;
Bench, AJ ;
Boyd, EM ;
Curtin, N ;
Scott, MA ;
Erber, WN ;
Green, AR .
LANCET, 2005, 365 (9464) :1054-1061
[7]   Myeloproliferative disorders [J].
Bench, AJ ;
Cross, NCP ;
Huntly, BJP ;
Nacheva, EP ;
Green, AR .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2001, 14 (03) :531-551
[8]  
Farag SS, 2002, INT J ONCOL, V21, P1041
[9]   Chromosome and molecular abnormalities in myelodysplastic syndromes [J].
Fenaux, P .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2001, 73 (04) :429-437
[10]   International scoring system for evaluating prognosis in myelodysplastic syndromes [J].
Greenberg, P ;
Cox, C ;
LeBeau, MM ;
Fenaux, P ;
Morel, P ;
Sanz, G ;
Sanz, M ;
Vallespi, T ;
Hamblin, T ;
Oscier, D ;
Ohyashiki, K ;
Toyama, K ;
Aul, C ;
Mufti, G ;
Bennett, J .
BLOOD, 1997, 89 (06) :2079-2088